Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Epidemiology and treatment of multiple sclerosis in elderly populations.

Vaughn CB, Jakimovski D, Kavak KS, Ramanathan M, Benedict RHB, Zivadinov R, Weinstock-Guttman B.

Nat Rev Neurol. 2019 Jun;15(6):329-342. doi: 10.1038/s41582-019-0183-3. Review.

PMID:
31000816
2.

Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium.

Vaughn CB, Kavak KS, Dwyer MG, Bushra A, Nadeem M, Cookfair DL, Ramanathan M, Benedict RH, Zivadinov R, Goodman A, Krupp L, Motl RW, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium.

Mult Scler. 2020 Jan;26(1):99-108. doi: 10.1177/1352458518816619. Epub 2018 Dec 3.

PMID:
30507270
3.

Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage.

Jakimovski D, Weinstock-Guttman B, Hagemeier J, Vaughn CB, Kavak KS, Gandhi S, Bennett SE, Fuchs TA, Bergsland N, Dwyer MG, Benedict RHB, Zivadinov R.

J Neurol Sci. 2018 Oct 15;393:128-134. doi: 10.1016/j.jns.2018.08.020. Epub 2018 Aug 23.

PMID:
30165291
4.

Fatigue and Mood States in Nursing Home and Nonambulatory Home-Based Patients with Multiple Sclerosis.

Younus Z, Vaughn CB, Sanai SA, Kavak KS, Gupta S, Nadeem M, Teter BE, Noyes K, Zivadinov R, Edwards K, Coyle PK, Goodman A, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium.

Int J MS Care. 2017 Nov-Dec;19(6):297-302. doi: 10.7224/1537-2073.2016-058.

5.

Ketogenic diet: Predictors of seizure control.

Agarwal N, Arkilo D, Farooq O, Gillogly C, Kavak KS, Weinstock A.

SAGE Open Med. 2017 Jun 6;5:2050312117712887. doi: 10.1177/2050312117712887. eCollection 2017.

6.

Time interval providing highest yield for initial EEG in patients with new onset seizures.

Sofat P, Teter B, Kavak KS, Gupta R, Li P.

Epilepsy Res. 2016 Nov;127:229-232. doi: 10.1016/j.eplepsyres.2016.08.024. Epub 2016 Aug 31.

PMID:
27639127
7.

Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.

Gaindh D, Kavak KS, Teter B, Vaughn CB, Cookfair D, Hahn T, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium.

J Neurol Sci. 2016 Nov 15;370:13-17. doi: 10.1016/j.jns.2016.09.005. Epub 2016 Sep 9.

PMID:
27772741
8.

Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation.

Weinstock-Guttman B, Hagemeier J, Kavak KS, Saini V, Patrick K, Ramasamy DP, Nadeem M, Carl E, Hojnacki D, Zivadinov R.

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):937-43. doi: 10.1136/jnnp-2015-312221. Epub 2016 Jan 18.

PMID:
26780938
9.

Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients.

Chouhfeh L, Kavak KS, Teter BE, Weinstock-Guttman B.

Mult Scler Relat Disord. 2015 May;4(3):228-33. doi: 10.1016/j.msard.2015.02.004. Epub 2015 Feb 27.

PMID:
26008939
10.

Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset.

Kavak KS, Teter BE, Hagemeier J, Zakalik K, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium.

Mult Scler. 2015 Jun;21(7):858-65. doi: 10.1177/1352458514555787. Epub 2014 Nov 12.

PMID:
25392327

Supplemental Content

Loading ...
Support Center